Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option ...

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus… [+18694 chars]
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - FHMnews